Artikel
Bone preserving short stem: mid-term results with special regard to AVN of the hip
Suche in Medline nach
Autoren
-
Wolf Drescher
- Dept. of Orthopedics and Traumatology, Rummelsberg Hospital, Schwarzenbruck, Germany
-
Richard Häne
- Dept. of Orthopedics and Traumatology, Rummelsberg Hospital, Schwarzenbruck, Germany
-
Thomas Pufe
- Universitätsklinik Aachen, Institut für Anatomie und Zellbiologie, Aachen, Germany
-
David Merschin
- BG Klinikum Unfallkrankenhaus Berlin, Klinik für Unfallchirurgie und Orthopädie, Berlin, Germany
| Veröffentlicht: | 23. Oktober 2017 |
|---|
Gliederung
Text
Objectives: Although short-stem hip prosthesis are increasingly used for total hip arthroplasty, mid- and long-term results are rare. Furthermore, some studies do not have sufficient case numbers. A possible indication is avascular necrosis of the hip.
Our retrospective study investigates the mid-term functional outcome and the revision rate following implantation of the curved Metha®-short-stem prosthesis comparing AVN of the hip to other indictions in a larger patient pool.
Methods: From 06/2005 until 01/2014 a total of 334 short stem hip prosthesis were implanted, 308 complete data sets were registered. A retrospective analysis was performed using the Oxford hip score. All revisions were registered.
Results: In a total of 308 prosthesis, the Oxford hip score was "excellent" in 67,9 %, "good" in 11 %, "fair" in 13,3 % and "poor" in 7,8 % with a mean follow-up of 59,6 months (SD ±28,8; range 12-115). In 24 cases AVN of the hip was the indication (7,8 %). The Oxford hip score was "excellent" in 66,7 %, "good" in 0,0 %, "fair" in 20,8 % and "poor" in 12,5 %. The cumulated 5-year-survival-rate was 97,3 %.
Conclusion: In mid-term observation, the Metha®-short-stem-prosthesis shows in comparison to a standart hip stem no disadvantage in functional outcome and in survival time. Providing a correct indication, the neck-preserving Metha®-short-stem is a valuable option in total hip arthroplasty for younger patients. The evaluation has shown no significant differences between aseptic osteonecrosis and other indications. Long-term data are needed.
